ProfileGDS5678 / 1450246_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 54% 55% 58% 56% 54% 58% 58% 54% 54% 54% 55% 54% 54% 55% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.3975754
GSM967853U87-EV human glioblastoma xenograft - Control 23.3545355
GSM967854U87-EV human glioblastoma xenograft - Control 33.4765158
GSM967855U87-EV human glioblastoma xenograft - Control 43.3781556
GSM967856U87-EV human glioblastoma xenograft - Control 53.2723454
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.5731558
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.5662158
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.3409254
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.305854
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.3103254
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.3490955
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.2934954
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.359254
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.3873555